Tumors of the liver, bile ducts, intestines, pancreas
Conditions
Interventions
Group 1: In patients with tumors of the liver, bile ducts, intestine or pancreas, 1.2 ml of blood is collected before and after chemotherapy or surgery. The blood is treated in vitro with lipopolysacc
Sponsors
Uniklinik RWTH Aachen Allg.-, Viszeral- & Transplantationschirurgie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients requiring surgical or chemotherapeutic treatment for cancer of the liver, bile ducts, intestines or pancreas.
Exclusion criteria
Exclusion criteria: Minors, pregnant women, persons incapable of giving consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study aims to address the following questions - What is the variability of inducible cytokine formation for each tumor entity? - Are there characteristic values for the different tumor entities? - Does inducible cytokine production correlate with primary tumor staging? - Are there differences between the healthy comparison group and the different tumor entities? - Does inducible cytokine formation change with tumor removal or chemotherapeutic treatment? | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives are to determine the prognostic value of cytokine production for progression-free survival and to gain insight into the association of inducible cytokine production with vitamin D, C-reactive protein (CRP), and monocyte and lymphocyte counts. | — |
Countries
Germany
Contacts
Public ContactThorsten Cramer
Uniklinik RWTH Aachen Allg.-, Viszeral- & Transplantationschirurgie
Outcome results
None listed